

Remdesivir for Covid-19 pneumonia in patients with severe chronic kidney disease: Case series and review of the literature

Ahmad Al Bishawi¹, Hamad Abdel Hadi¹, Eman Elmekaty¹, Musaed Al Samawi¹, Arun Nair¹, mohamed aboukamar¹, Muna AlMaslamani², and Alaaeldin Abdelmajid³

¹Hamad Medical Corporation

²Hamad Medical Corp

³Hamad General Hospital

January 3, 2022

Abstract

Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID-19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.

Hosted file

Remdesivir_-_Final- Submitted.docx available at <https://authorea.com/users/438539/articles/551402-remdesivir-for-covid-19-pneumonia-in-patients-with-severe-chronic-kidney-disease-case-series-and-review-of-the-literature>